Core Insights - DermFx has been selected as a key partner for Obagi Medical's ALOHA Program, focusing on real-world data generation to validate the clinical safety and efficacy of Obagi's Hyaluronic Acid products in everyday practice [1][2] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare with over 35 years of experience, known for addressing various skin concerns and recognized as the fastest-growing professional skincare brand in the U.S. in 2024 [5] - DermFx is a top-ranked medical spa in Southern California, specializing in advanced aesthetic treatments and has served tens of thousands of patients over 20+ years, emphasizing exceptional patient care and personalized protocols [6][7] - Waldencast plc, the parent company of Obagi Medical, aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands [8] Partnership Details - The partnership aims to provide DermFx with access to cutting-edge protocols and real-world insights, enhancing patient outcomes and allowing independent med spas to compete effectively [2][3] - The ALOHA Real-World Program will offer DermFx providers hands-on experience with Obagi saypha MagIQ™, utilizing proprietary technology for improved aesthetic results [3] Program Objectives - The ALOHA Program is designed to drive patient satisfaction and strengthen relationships between patients and DermFx providers through structured evaluations and standardized data capture [2] - Initial findings from the program will be presented at internal team meetings and regional events to highlight the benefits of the new protocols and products [2]

Core Insights - Moxie has been selected as a strategic partner for Obagi Medical's ALOHA Program due to its commitment to innovation and support for aesthetic entrepreneurs [1][3] - The partnership aims to enhance the integration of Obagi's saypha® MagIQ™ filler into aesthetic practices, leveraging Moxie's data-driven insights and operational tools [2][4] Company Overview - Obagi Medical is recognized as a leading innovator in physician-dispensed skincare, with over 35 years of experience in addressing various skin concerns [5] - The company is noted for its rapid growth, being the fastest-growing professional skincare brand in the U.S. in 2024 [5] Partnership Details - The ALOHA Program will evaluate clinical performance and patient experience while providing integrated protocols to improve satisfaction and loyalty among patients [3][4] - Moxie's software and coaching will support practices of all sizes, aligning with Obagi's Aesthetics for All™ ethos [4] Product Information - Obagi's saypha® MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology for stable hyaluronic acid delivery, aiming for natural-looking results [4]

Core Insights - Obagi Medical has launched two new lip products, the Obagi Lip Therapy AHA + PHA Smoothing Micro-Peel and the Obagi Lip Therapy Soothe & Protect Lip Treatment SPF 30, as part of a targeted treatment protocol for lip care [1][2]. Product Details - The Lip Therapy protocol is designed for nightly rejuvenation and daily protection, focusing on the delicate lip area to improve texture, restore hydration, and protect against environmental stressors [2][5]. - The AHA + PHA Smoothing Micro-Peel features three resurfacing acids: Glycolic Acid, Lactic Acid, and Gluconolactone, along with Hyaluronic Acid and Argan Oil to enhance moisture retention and improve lip appearance [3][4]. - The Soothe & Protect Lip Treatment SPF 30 provides hydration and broad-spectrum sun protection, formulated with a plumping peptide complex, Calendula, Hyaluronic Acid, and Vitamin E to smooth fine lines and support the lip barrier [4]. Consumer Feedback - In consumer perception testing, a majority reported smoother, plumper, and more replenished lips immediately after application, with continued improvements in hydration and overall appearance within two weeks [5]. Company Background - Obagi Medical has over 35 years of experience in advanced skincare, initially recognized for its treatment of hyperpigmentation with the Obagi Nu-Derm® System, and is now the fastest-growing professional skincare brand in the U.S. as of 2024 [7]. Availability and Pricing - The Lip Therapy AHA + PHA Smoothing Micro-Peel is priced at $55, and the Soothe & Protect Lip Treatment SPF 30 is priced at $40, both available through professional channels and on Obagi.com starting February 3rd [6].

Core Insights - VIO Med Spa has been selected as a key franchise partner for Obagi Medical's Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program due to its commitment to clinical excellence and innovative aesthetic care [1][4] - The partnership aims to leverage VIO Med Spa's strengths in injectables and patient education to generate real-world evidence on the performance of Obagi® saypha® MagIQ™ filler [2][3] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare with over 35 years of experience, known for addressing various skin concerns and recognized as the fastest-growing professional skincare brand in the U.S. in 2024 [6][10] - VIO Med Spa is a nationally recognized franchise specializing in advanced aesthetic and wellness treatments, focusing on clinical excellence and patient safety across its numerous locations [7] Program Details - The ALOHA Program will conduct a structured, multi-site assessment of the filler, emphasizing both clinical performance and patient experience while providing comprehensive protocols to enhance satisfaction and outcomes [3][4] - The program will kick off with a two-day immersive training for the VIO network, aimed at standardizing data collection across participating locations [3]

Core Insights - Next Health has been selected as a key partner for Obagi Medical's ALOHA Program, focusing on personalized wellness and innovative aesthetic treatments [1] - The collaboration aims to conduct a structured assessment of Obagi's saypha MagIQ™ filler, leveraging Next Health's expertise in holistic protocols and patient-centric education [2] Company Overview - Obagi Medical is recognized for its advanced skincare solutions, with over 35 years of experience, and is the fastest-growing professional skincare brand in the U.S. as of 2024 [6][10] - Next Health, founded in 2016, specializes in health optimization and longevity, offering services like IV therapy and hormone optimization through a network of wellness centers [7] Program Details - The ALOHA Program evaluates clinical efficacy and patient experience, aiming to enhance satisfaction and loyalty through integrated Obagi protocols [3] - Standardized data will be collected across Next Health locations, with initial findings to be shared at leadership meetings and major industry conferences [3] Technology and Innovation - Obagi's saypha MagIQ™ utilizes proprietary MACRO Core Technology for a stable hyaluronic acid matrix, designed to deliver natural-looking results with high performance [4]

Core Insights - Obagi Medical has partnered with Alpha Aesthetic Partners for the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program, highlighting a commitment to innovation and education in aesthetic medicine [1][4] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare with over 35 years of experience, focusing on various skin concerns including hyperpigmentation and premature aging [6] - Alpha Aesthetics Partners, founded in 2023, aims to advance the medical aesthetics industry through best-in-class support and clinical training, with a growing presence across 31 locations in 12 states [7] Program Details - The ALOHA Program will involve a structured, multi-site evaluation of Obagi's saypha MagIQ™ across Alpha's network, aiming to generate real-world evidence of the product's integration into clinical environments [2][3] - The program will collect standardized data to evaluate clinical performance and patient experience, with initial findings to be presented at the upcoming Alpha Summit [3] Product Information - Obagi's saypha MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology for a stable hyaluronic acid matrix, designed to deliver natural-looking results with high performance [4]

Core Insights - Obagi Medical has partnered with Alpha Aesthetic Partners for the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program, highlighting a commitment to innovation and education in aesthetic medicine [1][4] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare with over 35 years of experience, known for addressing various skin concerns and recognized as the fastest-growing professional skincare brand in the U.S. in 2024 [6][10] - Alpha Aesthetics Partners, founded in 2023, aims to advance the medical aesthetics industry through best-in-class support and clinical training, with a growing presence across 31 locations in 12 states [7] Program Details - The ALOHA Program will involve a structured, multi-site evaluation of Obagi saypha MagIQ™ across Alpha's network, focusing on generating real-world evidence of the product's integration into clinical environments [2][3] - The program aims to assess both clinical performance and patient experience, with standardized data collection across participating practices, and initial findings to be presented at the upcoming Alpha Summit [3] Product Information - Obagi saypha ChIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable hyaluronic acid matrix, designed for natural-looking results and high performance [4]

Core Insights - Obagi Medical has selected Platinum Dermatology Partners as the launch partner for its ALOHA Program, focusing on the integration of clinical evidence into everyday practice [1][2] Company Overview - Obagi Medical is recognized for its innovative physician-dispensed skincare solutions and has over 35 years of experience in the industry, particularly in treating skin concerns like hyperpigmentation and premature aging [6] - Platinum Dermatology Partners operates over 120 locations with nearly 400 providers across multiple states, emphasizing a collaborative practice model to enhance patient care [7] Program Details - The ALOHA Program aims to generate real-world data to validate the safety and efficacy of Obagi's products, specifically the saypha MagIQ injectable, through hands-on experience and structured evaluations [2][3] - Initial findings from the ALOHA Program will be presented at the annual Platinum Summit in September, showcasing the benefits of the new product within the Platinum network [4] Strategic Intent - The partnership with Platinum signifies Obagi's commitment to launching new injectables based on robust clinical evidence and integrated patient outcomes, aligning with the company's innovative approach to product development [5]

Core Insights - Obagi Medical has selected Platinum Dermatology Partners as the first partner for its ALOHA Program, emphasizing a commitment to clinical evidence and practice dissemination [1][5] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare and aesthetic solutions, part of Waldencast plc, with over 35 years of experience in advanced skincare [6] - Platinum Dermatology Partners operates over 120 locations with nearly 400 providers across multiple states, focusing on exceptional dermatology practices [7] - Waldencast plc aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands [8] Partnership Details - The partnership aims to generate real-world data to translate clinical safety and efficacy from FDA trials into everyday practice [2] - The ALOHA Real-World Program will provide hands-on experience with Obagi saypha MagIQ, enhancing patient satisfaction and provider relationships [3] - Initial findings from the program will be presented at the annual Platinum Summit and key industry conferences to showcase the product's real-world impact [4] Product Information - Obagi saypha MagIQ™ utilizes proprietary MACRO Core Technology for a stable hyaluronic acid matrix, designed for natural-looking results and high performance [5]

Core Insights - Obagi Medical has launched the ALOHA Program aimed at driving innovation in aesthetic practices through real-world evidence and insights [1][2] - The program will support the introduction of Obagi saypha MagIQ™, the first FDA-approved injectable hyaluronic acid filler from the company, featuring high usable HA content and a predictable injection profile [1][2] Company Overview - Obagi Medical is recognized as a leading innovator in physician-dispensed skincare with over 35 years of experience, initially known for its Obagi Nu-Derm System targeting hyperpigmentation [3] - The company is the fastest-growing professional skincare brand in the U.S. as of 2024, focusing on various skin concerns including aging, photodamage, and acne [3] Program Details - The ALOHA Program will gather real-world data from diverse practice settings to demonstrate the effectiveness of Obagi saypha MagIQ™ and its skincare products in enhancing practice success and patient satisfaction [2] - Participants in the program will provide structured feedback through standardized surveys, creating a comprehensive evaluation of the new HA injectable beyond traditional clinical trials [2] Industry Context - Waldencast plc, the parent company of Obagi Medical, aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands, ensuring agility and market responsiveness [4] - The company's strategy includes leveraging operational scale and expertise in managing beauty brands to mitigate category fluctuations and enhance brand performance [4]